Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01) PAR-15-120
Next due date: June 30, 2015
The goals of this initiative are to identify gene variants of traits associated with addiction and substance abuse in selectively bred, and outbred non-human animal models using methodologies of Next Gen-Sequencing, mapping, and genotyping.
This FOA will replace PAR-14-010 "Identification of Gene Variants for Addiction Related Traits by Next-Gen Sequencing in Model Organisms Selectively Bred for Addiction Traits (UH2/UH3)".
BRAIN Initiative NSF Funding Opportunity - Cracking the Olfactory Code NSF 15-547
Preliminary Proposal Due Date(s) (required) (due by 5 p.m. proposer's local time): May 01, 2015
Full Proposal Deadline(s) (due by 5 p.m. proposer's local time): July 31, 2015
NSF is launching a special activity as part of NSF's engagement in President Obama's BRAIN Initiative. A link to this activity, an Ideas Lab focused on "Cracking the Olfactory Code," can be found here: http://www.nsf.gov/pubs/2015/nsf15547/nsf15547.htm?org=NSF. The aim of this Ideas Lab to facilitate the generation and execution of innovative research projects aimed at understanding the nature of olfactory processing and sensory representations in the brain in general. The aspiration is that bringing together researchers from diverse scientific backgrounds will engender fresh thinking and innovative approaches that will transform our understanding of olfactory processing in behavioral contexts while spawning new opportunities to elucidate the general nature of sensory representations in the brain.
Notice of the National Institute on Drug Abuse (NIDA) Participation in PAR-15-070 "Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)" (NOT-DA-15-045)
National Institute on Drug Abuse
The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in PAR-15-070 "Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)" - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-DA-15-045.html#sthash.2gfwhbVJ.dpuf
Notice of the National Institute on Drug Abuse (NIDA) Participation in PAR-15-071 "Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)" (NOT-DA-15-046)
National Institute on Drug Abuse
The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in PAR-15-071 "Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)". - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-DA-15-046.html#sthash.My8Fw0RD.dpuf
NIDA has reissued its Program Announcements (PAs) soliciting collaborative research proposals between investigators from domestic U.S. institutions and researchers in other countries. The PAs—International Research Collaboration on Drug Abuse and Addiction Research—will be in effect until May 8, 2018.
Researchers may choose one of three grant programs in response to these broad calls for innovative research proposals: R01, R21, or R03.
Applications are encouraged in all areas of NIDA-supported science, including basic laboratory studies, clinical studies, epidemiological studies, community-based studies, and services research. Research priority areas include:
- Linkages between HIV/AIDS and drug abuse
- Amphetamine-type stimulants abuse
- Synthetic and other designer drug abuse
- Inhalant abuse
- Smoking during pregnancy
- Drugged driving
- Projects that address NIDA's Divisional research priorities and crosscutting research issues.
New BD2K Funding Opportunity, Supplements to Support Interoperability of NIH Funded Biomedical Data Repositories (Admin Supp) PA-15-144. http://grants.nih.gov/grants/guide/pa-files/PA-15-144.html
Application Receipt Date(s): April 20, 2015
Valentina Di Francesco
National Human Genome Research Institute (NHGRI)
NIH is accepting administrative supplement requests to support projects that will establish or improve interoperability among NIH funded biomedical data repositories. Improved interoperability is expected to lead to increased efficiency of repositories' operations and cost reductions, which are significant factors of the NIH's long-term sustainability plans for the biomedical data repositories.
Each supplement request should be associated to a collaborative project consisting of a biomedical data repository supported by an active NIH-funded parent grant, and one or more collaborating sites that together implement the interoperability goals of this FOA. The collaborating sites may be other biomedical data repositories, or may provide computational tools and data standards, or perform other activities that facilitate interoperability among data repositories. Supplement requests will only be accepted from active NIH-funded parent grants that primarily support biomedical data repositories with an overall annual budget above $500,000 in direct costs.
Big Data to Knowledge (BD2K) Advancing Biomedical Science Using Crowdsourcing and Interactive Digital Media (UH2) RFA-CA-15-006
The NIH Big Data to Knowledge (BD2K) is pleased to announce the release of a new RFA, "Big Data to Knowledge (BD2K) Advancing Biomedical Science Using Crowdsourcing and Interactive Digital Media (UH2)". This RFA seeks to support the development of new or significantly adapted interactive digital media that engages the public, experts or non-experts, in performing some aspect of biomedical research via crowdsourcing. To be responsive to this FOA, each application is expected to pose a challenging biomedical research problem and propose the development of engaging interactive digital media that incorporates crowdsourcing as a fundamental component of how the problem is solved.
BD2K was established to address the opportunities and challenges presented by the dawning era of big data in biomedical research. BD2K is a trans-NIH initiative that supports a variety of related efforts designed to enhance the utility of biomedical big data with the goals of cultivating the digital research enterprise within biomedicine, facilitating discovery, and to maximizing community engagement. For more information about BD2K please see http://bd2k.nih.gov/index.html.
Please share this information with your colleagues.
Letters of Intent Date: May 3, 2015
Receipt Date: June 3, 2015
Program Contact: David J. Miller, Ph.D.
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to firstname.lastname@example.org Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contact email@example.com 301-435-1309